Browse > Article

Predictors of Failed Closure of Patent Ductus Arteriosus with the First Course of Indomethacin in Preterm Infants  

Lee, Mong-Young (Aideul Pediatric Clinic)
Lim, Dong-Hee (Department of Pediatrics, Korea University, School of Medicine)
Park, Kyu-Hee (Department of Pediatrics, Korea University, School of Medicine)
Ha, Gi-Su (Department of Pediatrics, Korea University, School of Medicine)
Lee, Jang-Hoon (Department of Pediatrics, Korea University, School of Medicine)
Choi, Byung-Min (Department of Pediatrics, Korea University, School of Medicine)
Hong, Young-Sook (Department of Pediatrics, Korea University, School of Medicine)
Yoo, Kee-Hwan (Department of Pediatrics, Korea University, School of Medicine)
Lee, Joo-Won (Department of Pediatrics, Korea University, School of Medicine)
Publication Information
Neonatal Medicine / v.17, no.1, 2010 , pp. 75-83 More about this Journal
Abstract
Purpose : This study was performed to determine the predictors of failed closure of a patent ductus arteriosus (PDA) following the first course of indomethacin in symptomatic preterm infants. Methods : Forty three of 43 preterm infants, admitted to the neonatal intensive care unit diagnosed with PDA and treated with indomethacin at the Korea University Medical Center between January 1990 and October 2007, ware studied. The perinatal risk factors affecting the failed closure of PDA were retrospectively assessed. Results : The failed PDA closure group included 16 (37%) out of 43 infants three of whom underwent surgery. The closure group included 27 (63%) out of 43 infants. In the failed closure group, the Apgar scores (1 min, 5 min) were significantly higher (P<0.05) and antenatal steroid administration was significantly lower (P<0.05). In addition, dopamine administration was significantly lower (P<0.05) and the mean postnatal age at diagnosis was significantly lower (P<0.05). Multiple logistic regression for the prediction of failed PDA closure found only antenatal steroid administration (OR 0.092, CI 0,010-0.826, P=0.0331) as an associated factor. Conclusion : In patients with antenatal steroid administration the failed PDA closure rate was significantly lower. Therefore, antenatal steroid administration can be considered as an important factor for the closure of PDA in preterm pregnancies.
Keywords
Ductus Arteriosus; Patent; Indomethacin; Infant; Premature;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000;343:728-30.   DOI   ScienceOn
2 Hammerman C, Kaplan M. Comparative tolerability of pharmacological treatments for patent ductus arteriosus. Drug Saf 2001;24:537-51.   DOI   ScienceOn
3 Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin inpreterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 2005;19:187-93.   DOI   ScienceOn
4 Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005;30:121-32.   DOI   ScienceOn
5 Aggarwal R, Bajpai A, Deorari AK, Paul VK. Patent ductus arteriosus in preterm neonates. Indian J Pediatr 2001;68:981-4.   DOI   ScienceOn
6 Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895-906.   DOI
7 Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 1996;128:601-7.   DOI   ScienceOn
8 Merritt TA, Harris JP, Roghmann K, Wood B, Campanella V, Alexson C, et al. Early closure of the patent ductus arteriosus in very lowbirth-weight infants: a controlled trial. J Pediatr 1981;99:281-6.   DOI
9 Lee JH, Lee SJ, Hong JS, Han HS, Park BS. Surgical ligation of the patent ductus arteriosus in very low birth weight premature infants: clinical comparison between indomethacin therapy and early surgical ligation. Chungbuk Med J 2000;10:150-8.
10 Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009;123:e138-44.   DOI
11 Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001;138:205-11.   DOI   ScienceOn
12 Drougia A, Giapros V, Krallis N, Theocharis P, Nikaki A, Tzoufi M, et al. Incidence andrisk factors for cerebral palsy in infants with perinatal problems: a 15-year review. Early Hum Dev 2007;83:541-7.   DOI   ScienceOn
13 Moin F, Kennedy KA, Moya FR. Risk factors predicting vasopressor use after patent ductus arteriosus ligation. Am J Perinatol 2003;20:313-20.   DOI   ScienceOn
14 Noori S, Friedlich P, Seri I, Wong P. Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants. J Pediatr 2007;150:597-602.   DOI   ScienceOn
15 Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007;150:229-34, 34e1.   DOI   ScienceOn
16 Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007;119:1165-74.   DOI   ScienceOn
17 Clyman R, Cassady G, Kirklin JK, Collins M, Philips JB 3rd. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009;154:873-6.   DOI   ScienceOn
18 Clyman RI, Seidner SR, Kajino H, Roman C, Koch CJ, Ferrara N, et al. VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. Am J Physiol Regul Integr Comp Physiol 2002;282:R199-206.   DOI
19 Clyman RI, Chan CY, Mauray F, Chen YQ, Cox W, Seidner SR, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res 1999;45:19-29.   DOI   ScienceOn
20 Narayanan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000;136:330-7.   DOI   ScienceOn
21 Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007;151:629-34.   DOI   ScienceOn
22 Boo NY, Mohd-Amin I, Bilkis AA, Yong-Junina F. Predictors of failed closure of patent ductus arteriosus with indomethacin. Singapore Med J 2006;47:763-8.
23 Costa S, Zecca E, De Luca D, De Carolis MP, Romagnoli C. Efficacy of a single dose of antenatal corticosteroids on morbidity and mortality of preterm infants. Eur J Obstet Gynecol Reprod Biol 2007;131:154-7.   DOI   ScienceOn
24 Eronen M, Kari A, Pesonen E, Hallman M. The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus. A randomized double-blind study. Am J Dis Child 1993;147:187-92.   DOI
25 Clyman RI, Waleh N, Black SM, Riemer RK, Mauray F, Chen YQ. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension, and vasa vasorum. Pediatr Res 1998;43:633-44.   DOI   ScienceOn
26 Shaffer CL, Gal P, Ransom JL, Carlos RQ, Smith MS, Davey AM, et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 2002;30:343-8.   DOI   ScienceOn
27 Supapannachart S, Khowsathit P, Patchakapati B. Indomethacin prophylaxis for patent ductus arteriosus(PDA) in infants with a birth weight of less than 1250 grams. J Med Assoc Thai 1999;82 Suppl 1:S87-92.
28 Salhab WA, Hynan LS, Perlman JM. Partial or complete antenatal steroids treatment and neonatal outcome in extremely low birth weight infants < or =1000 g: is there a dose-dependent effect? J Perinatol 2003;23:668-72.   DOI   ScienceOn
29 Tsai MY, Brown DM. Effect of dexamethasone on fetal lung 15-hydroxy-prostaglandin dehydrogenase: possible mechanism for the prevention of patent ductus arteriosus by maternal dexamethasone therapy. Prostaglandins Leukot Med 1987;27:237-45.   DOI
30 Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972;24:1-29.
31 Cheung PY, Barrington KJ. Renal dopamine receptors: mechanisms of action and developmental aspects. Cardiovasc Res 1996;31:2-6.   DOI
32 Manoogian C, Nadler J, Ehrlich L, Horton R. The renal vasodilating effect of dopamine is mediated by calcium flux and prostacyclin release in man. J Clin Endocrinol Metab 1988;66:678-83.   DOI
33 Barrington K, Brion LP. Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. Cochrane Database Syst Rev 2002;(3):CD003213.